Akèy › Kansè tete negatif triple › Delaware › Newark
Etid klinik pou Kansè tete negatif triple nan Newark, DE
3 etid pou Kansè tete negatif triple ap chèche patisipan nan sit nan ak bò kote Newark (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Ap rekriteFaz 1/2
- Medical Oncology Hematology Consultants, Newark
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Ap rekriteFaz 3
- Helen F. Graham Cancer Center & Research Institute ( Site 0018), Newark
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Ap rekriteFaz 2/3
- Medical Oncology Hematology Consultants, PA, Newark
Etid Kansè tete negatif triple nan lòt vil
- Houston, TX42 etid
- New York City, NY31 etid
- Nashville, TN28 etid
- Los Angeles, CA27 etid
- Boston, MA26 etid
- San Antonio, TX23 etid
- St. Louis, MO21 etid
- Atlanta, GA20 etid
- Arlington, VA20 etid
- Dallas, TX18 etid
- Chicago, IL16 etid
- Columbus, OH16 etid
Lòt etid nan Newark
- Kansè Poumon ki pa ti selil16 etid
- Kansè pwostat10 etid
- Kansè kolorektal9 etid
- Kansè poumon9 etid
- Kansè nan tete8 etid
- Kansè Metastatik7 etid
- Kansè (tout kalite)6 etid
- Kansè pankreyas6 etid
- Kansè ovè5 etid
- Limfòm folikilè4 etid
- Lukemi lenfositè kwonik4 etid
- Kansè lestomak4 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.